• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Koffey Quentin was granted 4,040 shares, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

    2/11/25 4:48:51 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Koffey Quentin

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Azenta, Inc. [ AZTA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/07/2025 A 4,040(1) A $0(2) 5,035 D
    Common Stock 4,611,752 I See footnotes(3)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Annual grant of unrestricted shares under the Issuer's 2020 Equity Incentive Plan in connection with the Reporting Person's service on the Issuer's Board of Directors (the "Board"). The number of shares was determined based on an annual grant amount of $215,000 and a price per share of $52.32 based on the average daily closing price for the 20 trading-day period immediately preceding and including February 7, 2025.
    2. No amount was paid upon grant of the shares.
    3. By virtue of the Reporting Person's position as ultimately controlling various entities that hold shares in the Issuer, the Reporting Person may be deemed to be the beneficial owner of these shares for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of any of these shares, except to the extent of any pecuniary interest therein.
    4. The Reporting Person continues to serve as a director of the Board and, as a result, the entities referenced in footnote 3 are directors by deputization for purposes of Section 16 of the Exchange Act.
    /s/ Quentin Koffey 02/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Marotta John was granted 1,000 units of Common, increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:30:06 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: President and CEO Marotta John was granted 5,434 units of Common, increasing direct ownership by 5% to 106,296 units (SEC Form 4)

      4/A - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:10:08 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 12,000 units of Common, increasing direct ownership by 238% to 17,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/3/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    SEC Filings

    See more
    • SEC Form SD filed by Azenta Inc.

      SD - Azenta, Inc. (0000933974) (Filer)

      5/30/25 4:15:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/16/25 4:12:24 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development

      Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy wi

      5/13/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology